Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer. | Synapse
Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer.
The aim is to explore the therapeutic potential of minibodies targeting galectin-1 and galectin-7 in triple-negative breast cancer (TNBC).
Engineered minibodies were developed to block galectin-1 and galectin-7.
The study assessed their effects on immune functions and cancer progression in TNBC models.
Immunotherapy strategies leveraging these minibodies were evaluated for efficacy.
Selective blockade of galectin-1 and galectin-7 enhanced anti-tumor immune responses.
Therapeutic treatment led to significant tumor regression in TNBC models, showing a marked increase in T-cell activity.
Results indicate potential for expanded immunotherapy options targeting glyco-immune pathways.
Abstract
Tregs. These findings demonstrate that selective GAL blockade with engineered minibodies is a promising strategy to expand immunotherapy options in TNBC.